This infographic explores the strategic moves pharma leaders can make to help mitigate the end-of-exclusivity risks coming with the patent cliff.
The global pharmaceutical industry is approaching a major patent cliff while functioning in a marketplace that is far different from the last cliff of nearly twenty years ago. Today’s drugs in development target rare diseases or specialized therapeutic areas, making it difficult to replace the revenue generated by expiring mass-market primary-care medicines. And there are shifts that will ultimately transform the traditional patent model.
This infographic explores success stories from the strategic moves industry leaders can make to maintain their margins and protect the ability to innovate. Mature products can be positioned to mitigate the risks posted by the patent cliff. Highlights include:
- The ways geography, indications, and patient population can work together to expand a products reach.
- Digging into how a brand name brings value to mass-market and product mix angles.
- Whether rigorous cost-cutting can make it possible to maintain profitability of a post-patent product.
Offered Free by: BioPharma Dive’s Studio by Informa TechTarget and Cencora
See All Resources from: BioPharma Dive’s Studio by Informa TechTarget and Cencora
